Want to see ABVC full AI Analyst Report?
Top Page
ABVC BioPharma
(NASDAQ:ABVC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.97
▼(-3.56% Downside)
Action:Reiterated
Date:07/28/26
The score is driven primarily by weak financial performance—ongoing net losses, minimal TTM revenue, and persistent negative free cash flow—indicating elevated financing and execution risk. Technicals add pressure with the stock trading below all key moving averages. Valuation is also constrained because the company is loss-making (negative P/E) and offers no dividend support.
Positive Factors
Proprietary clinical-stage pipeline
ABVC's business model centers on advancing proprietary small-molecule and other candidates through clinical development. That focus creates durable value drivers: clinical data can enable regulatory filings or partnering/licensing deals, making pipeline progress a structural source of upside over coming months.
Negative Factors
Sustained unprofitability
Consistent, material net losses erode equity and limit internal reinvestment capacity. Over a 2-6 month horizon this persistent profitability gap increases the likelihood the company will need external capital, creating execution and dilution risk that weighs on long-term financial stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary clinical-stage pipeline
ABVC's business model centers on advancing proprietary small-molecule and other candidates through clinical development. That focus creates durable value drivers: clinical data can enable regulatory filings or partnering/licensing deals, making pipeline progress a structural source of upside over coming months.
Read all positive factors
ABVC BioPharma (ABVC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$26.82M
Dividend YieldN/A
Average Volume (3M)95.05K
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue Growth-100.00%
EPS Growth-170.04%
CountryUS
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding26,554,365
10 Day Avg. Volume116,541
30 Day Avg. Volume95,045
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)4.46
Price to Sales (P/S)0.00
P/FCF Ratio-16.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.3
Revenue Forecast (FY)$35.28M
ABVC BioPharma Business Overview & Revenue Model
Company Description
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key c...
How the Company Makes Money
null...
ABVC BioPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -795.95K | 0.00 | 509.59K | 152.43K | 969.78K | 355.80K |
| Gross Profit | -795.95K | 0.00 | 508.83K | -149.61K | 683.37K | 350.71K |
| EBITDA | -9.17M | -7.43M | -4.34M | -6.33M | -15.20M | -10.97M |
| Net Income | -9.42M | -7.91M | -4.90M | -7.79M | -16.42M | -12.84M |
Balance Sheet | ||||||
| Total Assets | 19.73M | 21.06M | 7.54M | 7.78M | 10.93M | 13.70M |
| Cash, Cash Equivalents and Short-Term Investments | 202.51K | 745.83K | 928.55K | 796.09K | 1.47M | 5.94M |
| Total Debt | 2.73M | 3.47M | 3.20M | 2.77M | 3.41M | 3.34M |
| Total Liabilities | 6.90M | 7.76M | 6.82M | 6.53M | 6.34M | 4.83M |
| Stockholders Equity | 10.77M | 11.11M | 1.23M | 1.55M | 4.45M | 8.84M |
Cash Flow | ||||||
| Free Cash Flow | -3.34M | -2.99M | -1.81M | -4.21M | -7.52M | -7.62M |
| Operating Cash Flow | -3.34M | -2.99M | -1.81M | -4.19M | -7.40M | -7.60M |
| Investing Cash Flow | -1.16M | -1.21M | 0.00 | -360.19K | -1.72M | -805.97K |
| Financing Cash Flow | 3.87M | 4.64M | 1.98M | 3.87M | 4.01M | 10.00M |
ABVC BioPharma Risk Analysis
ABVC BioPharma disclosed 48 risk factors in its most recent earnings report. ABVC BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Cybersecurity incidents and decentralization of documents may hurt the company's business, damage its reputation, increase its costs, and cause losses. Q4, 2023
ABVC BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $52.31M | -3.71 | 76.02% | ― | ― | -13.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $60.61M | -5.93 | -90.61% | ― | -35.84% | 67.41% | |
47 Neutral | $179.14M | -1.52 | -194.74% | ― | 160.53% | 12.32% | |
44 Neutral | $34.90M | -0.79 | -136.08% | ― | -77.56% | -50.38% | |
44 Neutral | $17.69M | -0.19 | -523.04% | ― | ― | 38.53% | |
41 Neutral | $26.82M | -8.79 | -92.03% | ― | -100.00% | -170.04% |
* Healthcare Sector Average
ABVC
ABVC BioPharma
1.01
-2.19
-68.44%
CRVO
CervoMed
2.58
-6.75
-72.35%
HYFT
MindWalk Holdings
1.29
-0.54
-29.51%
JSPR
Jasper Therapeutics
0.63
-2.34
-78.79%
INKT
MiNK Therapeutics
10.50
-2.72
-20.57%
CAMP
CAMP4 Therapeutics Corporation
3.45
1.81
110.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.